Kevin Kotler

Horizon Pharma PLC (HZNP), Flamel Technologies S.A. (ADR) (FLML) & More: Why Should You Consider Following Broadfin Capital’s Investment Moves?

At Insider Monkey, we think that an investor can beat the market by imitating smart moves of big hedge funds into the top pick they are bullish on.

Keep Reading →

November 14 - Hedge Funds, News - Comments

Qlt Inc (QLTI): Broadfin Capital Adds Another 820,000 Shares to its Position

We wrote recently about Qlt Inc (NASDAQ:QLTI) entering into an Agreement and Plan of Merger with its wholly-owned indirect subsidiary, Isotope Acquisition Corp., and Aegerion...

Keep Reading →

September 23 - Hedge Funds, News - Comments

Aegerion Pharmaceuticals Inc. (AEGR): Broadfin Capital Raises Its Stake Ahead of Merger

Back in June, Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Qlt Inc.

Keep Reading →

September 14 - Hedge Funds, News - Comments

Qlt Inc (QLTI): Broadfin’s Kevin Kotler to Become Director of Novelion

In June, Qlt Inc (NASDAQ:QLTI) signed an Agreement and Plan of Merger with its wholly-owned indirect subsidiary, Isotope Acquisition Corp., and Aegerion Pharmaceuticals, Inc...

Keep Reading →

September 14 - Hedge Funds, News - Comments

Recro Pharma Inc. (REPH): Largest Shareholder Broadfin Capital Buys Even More Shares

An amended 13D filing with the Securities and Exchange Commission showed that Kevin Kotler's Broadfin Capital has acquired more shares of Recro Pharma Inc.

Keep Reading →

August 18 - Hedge Funds, News - Comments

Kevin Kotler’s Healthcare Fund Broadfin Capital Just Had A Disastrous Q1

Though 2016 hasn't been great for the overall hedge fund industry so far, it is turning out to be an especially terrible year for biotech-focused hedge funds.

Keep Reading →

April 6 - Hedge Fund Analysis, Hedge Funds, News - Comments

Nevro Corp (NVRO): Broadfin Capital Jumps On February Swoon to Buy More Shares

Kevin Kotler's Broadfin Capital has filed a Form 13G disclosing an enlarged position of 1.46 million shares of Nevro Corp (NYSE:NVRO). The holding stood as Mr.

Keep Reading →

March 2 - Hedge Funds, News - Comments

Billionaire Icahn Salutes Xerox Corp (XRX)’s Split, Lasry Trims YRC Worldwide Inc. (YRCW) Stake, and Kotler Buys More Raptor Pharmaceutical Corp. (RPTP)

Although the average hedge fund has been struggling to beat broader market benchmarks in recent years, the hedge fund industry as a whole has been constantly growing.

Keep Reading →

January 29 - Hedge Funds, News - Comments

Bill & Melinda Gates Foundation Trust’s Latest Bet on China & Two Other Latest Hedge Fund Moves

At Insider Monkey, we focus mainly on the 13F filings of around 730 hedge funds and other institutional investors, in order to identify trading opportunities and benefit from ...

Keep Reading →

December 29 - Hedge Funds, News - Comments

Starboard Trims Office Depot Stake Amid FTC Challenging Merger with Staples; Broadfin Capital Buys More Derma Sciences Inc. (DSCI)

Some bright minds of the finance world believe that shareholder activism has surged in recent years because of increased market efficiency.

Keep Reading →

December 16 - Hedge Funds, News - Comments

What Do Hedge Funds Have To Say About These 3 Purchases?

Most hedge funds and other money managers tracked by Insider Monkey have not submitted their 13F filings for the September quarter just yet.

Keep Reading →

November 4 - Hedge Fund Analysis, Hedge Funds, News - Comments

The Proxy Battle Between Broadfin Capital and Cardica (CRDC) Is Heating Up Just As New CEO Is Unveiled

The battle between Broadfin Capital and the Board of Cardica, Inc. (NASDAQ:CRDC) is heating up.

Keep Reading →

October 5 - Hedge Funds, News - Comments

Hedge Funds See More Upside for Nevro Corp (NVRO) and WidePoint Corporation (WYY)

According to a recent 13G form filed with the Securities and Exchange Commission Kevin Kotler's (pictured) Broadfin Capital has added 1.18 million shares to its stake in Nevro...

Keep Reading →

September 25 - Hedge Funds, News - Comments

Contentious Proxy Battle Looms Between Broadfin Capital And Cardica, Inc. (CRDC)

Kevin Kotler's healthcare fund Broadfin Capital, the top performing fund in our database this year based on the calculated returns of its public equity positions in companies...

Keep Reading →

September 14 - Hedge Funds, News - Comments

Next Big Biotech Stock To Buy: Hedge Funds’ New Moves

Both Antares Pharma Inc (NASDAQ:ATRS) and Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) recently had their names attached to 13G forms, as two hedge funds raised their holdings...

Keep Reading →

September 10 - Hedge Funds, News - Comments

Broadfin Capital Increases Its Profitable Stake In Advaxis Inc. (ADXS) To 5.27%

As disclosed in a Schedule 13G filing with the U.S.

Keep Reading →

August 13 - Hedge Funds, News - Comments

Broadfin Capital and Bridger Management Think SeaSpine Holdings Corp (SPNE) Is Oversold

According to two recent filings with the Securities and Exchange Commission, Kevin Kotler's (pictured) Broadfin Capital and Roberto Mignone's Bridger Management have disclosed...

Keep Reading →

July 23 - Hedge Funds, News - Comments

Kevin Kotler’s Latest Move Lifts His Ownership In This Biotech Company To 5.92%

Kevin Kotler’s Broadfin Capital LLC, one of the leading healthcare-focused hedge funds, disclosed its ownership of nearly 1.48 million shares in Medgenics Inc.

Keep Reading →

July 19 - Hedge Funds, News - Comments

Healthcare Expert Kevin Kotler Boosts His Stake In Recro Pharma Inc. (REPH)

Kevin Kotler’s Broadfin Capital has filed a 13D with the Securities and Exchange Commission regarding its stake in Recro Pharma Inc. (NASDAQ:REPH).

Keep Reading →

July 16 - Hedge Funds, News - Comments

Broadfin Capital Discloses New Stake in This Canadian Biotechnology Company

Broadfin Capital, led by Kevin Kotler, has initiated a new position in QLT Inc. (USA) (NASDAQ:QLTI). In a new filing with the U.S.

Keep Reading →

June 29 - Hedge Funds, News - Comments

Broadfin Capital Thinks ContraFect Corp (CFRX) Can Prevent 25% of Deaths

According to a recent 13G form filed with the Securities and Exchange Commission, Kevin Kotler's Broadfin Capital has initiated a stake in ContraFect Corp (NASDAQ:CFRX) to the...

Keep Reading →

June 22 - Hedge Funds, News - Comments

Alere Inc (ALR), Lion Biotech (LBIO), Genocea Biosciences Inc (GNCA), Advaxis Inc (ADXS) Among Broadfin’s Top New Health Picks

Broadfin Capital, LLC is a New York-based hedge fund, whose $1.28-billion equity portfolio is invested in healthcare companies.

Keep Reading →

June 1 - Hedge Funds, News - Comments

Horizon Pharma PLC (HZNP), Apple Inc. (AAPL): How Billionaire Mark Kingdon’s Picks Performed in Q1

Kingdon Capital Management, a New-York based hedge fund, was founded by Mark E. Kingdon in 1983. Prior to this, he worked for AT&T and Century Capital Associates.

Keep Reading →

April 16 - Hedge Funds, News - Comments

Carbylan Therapeutics Inc (CBYL): Broadfin’s Latest Move and Market Smashing Q1 Returns Inside

To say Kevin Kotler’s Broadfin Capital had exceptional Q1 returns from its 11 long positions in companies valued at $1 billion or more would be a gross understatement.

Keep Reading →

April 16 - Hedge Funds, News - Comments

Ignyta Inc, Horizon Pharma PLC: Biotech Hedgie Kevin Kotler Enjoys Strong Gains

Kevin Kotler's Broadfin Capital has disclosed raising its passive stake in the micro-cap oncology biotechnology company Ignyta Inc (NASDAQ:RXDX).

Keep Reading →

March 25 - Hedge Funds, News - Comments

Broadfin Buffs Up on Zogenix, Inc. (ZGNX) and Derma Sciences Inc (DSCI)

In two separate filings today Kevin Kotler's Broadfin Capital has revealed increasing its passive stake in Zogenix, Inc.

Keep Reading →

March 19 - Hedge Funds, News - Comments

Tonix Pharmaceuticals Holding Corp., Manning & Napier Inc: Deerfield, Ariel Open Bullish New Positions

James E. Flynn’s Deerfield Management entered a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) this week. According to the 13G Form filed with the U.S.

Keep Reading →

February 10 - Hedge Funds, News - Comments

Epirus Biopharmaceuticals Inc (EPRS): These Two Funds Open New Positions

The days of having no fund activity in Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) are over.

Keep Reading →

February 9 - Hedge Funds, News - Comments

Alcobra Ltd (ADHD): Broadfin Capital and Deerfield Initiate Passive Stakes Following Public Offering

Kevin Kotler's Broadfin Capital and James Flynn's Deerfield Management have both initiated passive stakes in Alcobra Ltd (NASDAQ:ADHD).

Keep Reading →

January 20 - Hedge Funds, News - Comments

Digimarc Corp (DMRC), Eleven Biotherapeutics Inc (EBIO): Rima Senvest Management and Sabby Management Are Bullish on These Micro-Caps

Digimarc Corp (NASDAQ:DMRC) and Eleven Biotherapeutics Inc (NASDAQ:EBIO) are two companies on which two funds have been bullish recently.

Keep Reading →

December 3 - Hedge Funds, News - Comments

Dipexium Pharmaceuticals Inc (DPRX): Kingdon Capital Boosts Stake in Recently-Public Pharmaceutical Company

Mark Kingdon’s Kingdon Capital recently disclosed an increase in its exposure to Dipexium Pharmaceuticals Inc (NASDAQ:DPRX).

Keep Reading →

December 1 - Hedge Funds, News - Comments

Aegerion Pharmaceuticals, Inc. (AEGR): Broadfin Boosts Stake Getting on Board with Other Bullish Investors

Kevin Kotler's New York-based fund Broadfin Capital has boosted its position in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR).

Keep Reading →

November 7 - Hedge Funds, News - Comments

Cardica, Inc. (CRDC): Broadfin Capital Asks Other Shareholders to Support Its Crusade

Kevin Kotler’s Broadfin Capital doesn’t want to hear any more excuses from the Board of Cardica, Inc.

Keep Reading →

October 23 - Hedge Funds, News - Comments

Universal American Corporation (UAM): Camber Capital Management Resumes Buying Shares

Stephen Dubois’ Camber Capital Management is again increasing its stakes in Universal American Corporation (NYSE:UAM).

Keep Reading →

October 20 - Hedge Funds, News - Comments

Aegerion Pharmaceuticals Inc. (AEGR), Cytori Therapeutics Inc (CYTX): Scopia Capital and Sabby Capital Are Bullish on These Stocks

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) continues to feel hedge funds’ bullishness.

Keep Reading →

October 15 - Hedge Funds, News - Comments

Aegerion Pharmaceuticals, Inc. (AEGR): Steve Cohen’s Point72 Asset Management Goes Big

Life science is turning out to be an industry sector that most hedgies are convinced will outperform in the near future.

Keep Reading →

October 15 - Hedge Funds, News - Comments

PowerSecure International Inc. (POWR), Anthera Pharmaceuticals Inc (ANTH): Broadfin Capital and Becker Drapkin Management’s Recent Bullish Moves

Last Friday, Kevin Kotler’s Broadfin Capital disclosed a marked increase (of almost 70%) in its exposure to Anthera Pharmaceuticals Inc (NASDAQ:ANTH).

Keep Reading →

October 6 - Hedge Funds, News - Comments

Servicesource International Inc (SREV), Recro Pharma Inc (REPH): Altai Capital And Broadfin Capital’s Latest Moves

According to a recent filing with the Securities and Exchange Commission, Altai Capital, run by Rishi Bajaj, Toby Symonds and Steve Tesoriere, has increased its holding of ...

Keep Reading →

September 16 - Hedge Funds, News - Comments

Cardica Inc. (CRDC): Broadfin Capital, Kevin Kotler Send Another Letter To The Board

In a recent filing with the Securities and Exchange Commission, Broadfin Capital has disclosed a letter sent to the Board of Directors of Cardica, Inc. (NASDAQ:CRDC).

Keep Reading →

September 12 - Hedge Funds, News - Comments

Visium Asset Management Raises Exposure To Horizon Pharma Inc. (HZNP)

Visium Asset Management, managed by Jacob Gottlieb, has boosted its position in Horizon Pharma Inc. (NASDAQ:HZNP), a new filing with the U.S.

Keep Reading →

August 11 - Hedge Funds, News - Comments

Kevin Kotler, Broadfin Capital Add Some More Cardica, Inc. (CRDC) Shares To Their Portfolio

Kevin Kotler and his fund, Broadfin Capital, have further boosted their holding of Cardica, Inc. (NASDAQ:CRDC) stock.

Keep Reading →

July 25 - Hedge Funds, News - Comments

Kevin Kotler, Broadfin Capital Increase Holding Of Progenics Pharmaceuticals, Inc. (PGNX)

Kevin Kotler is bullish on Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and has decided to boost his fund's investment in the stock.

Keep Reading →

July 22 - Hedge Funds, News - Comments

Israel Englander and Millennium Management Further Decrease Exposure To Liberator Medical Holdings Inc (LBMH)

Israel Englander and Millennium Management have further decreased their stake in Liberator Medical Holdings Inc (NYSEMKT:LBMH) and have sold 175,000 shares in one transaction...

Keep Reading →

June 27 - Hedge Funds, News - Comments

RA Capital Management Sells 800,000 Shares of Achillion Pharmaceuticals Inc. (ACHN)

RA Capital Management, managed by Peter Kolchinsky, has sold 800,000 shares of Achillion Pharmaceuticals Inc.

Keep Reading →

June 25 - Hedge Funds, News - Comments

Camber Capital Management Reveals New Position in Cardica, Inc. (CRDC)

Stephen Dubois' Camber Capital Management revealed a new stake in Cardica, Inc. (NASDAQ:CRDC).

Keep Reading →

April 25 - Hedge Funds, News - Comments

Broadfin Capital Initiates New Positions In Corium International Inc (CORI), AMAG Pharmaceuticals Inc. (AMAG) and La Jolla Pharmaceutical Company (LJPC)

In three recent filings, Kevin Kotler’s Broadfin Capital has revealed adding three companies: Corium International Inc (NASDAQ:CORI), AMAG Pharmaceuticals Inc.

Keep Reading →

April 17 - Hedge Funds, News - Comments

Kevin Kotler’s Broadfin Capital Reveals New Stake in Dipexium Pharmaceuticals (DPRX)

A new filing with the SEC, Kevin Kotler and his hedge fund Broadfin Capital revealed new stake in Dipexium Pharmaceuticals, Inc (NASDAQ:DPRX).

Keep Reading →

April 9 - Hedge Funds, News - Comments

Kevin Kotler’s Broadfin Capital’s and MELA Sciences (MELA)

A new filing with the SEC revealed, Kevin Kotler and his hedge fund Broadfin Capital revealed a trimmed stake in MELA Sciences, Inc (NASDAQ:MELA).

Keep Reading →

April 4 - Hedge Funds, News - Comments

Sabby Management Adds Bioline RX Ltd (BLRX) & Recro Pharma Inc (REPH) to Its Equity Portfolio

In a couple of new filings with the SEC, Hal Mintz's Sabby Management disclosed adding two companies to its equity portfolio: Bioline RX Ltd (NASDAQ:BLRX) and Recro Pharma Inc...

Keep Reading →

March 17 - Hedge Funds, News - Comments